This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Disc Medicine (IRON)

Tipranks - Tipranks - Tue Jun 16, 11:23AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA) and Disc Medicine (IRON) with bullish sentiments.

Claim 55% Off TipRanks

Neumora Therapeutics, Inc. (NMRA)

William Blair analyst Myles Minter reiterated a Buy rating on Neumora Therapeutics, Inc. today. The company’s shares closed last Monday at $0.97.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 31.3% and a 57.0% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Entrada Therapeutics Inc. ;'>

Currently, the analyst consensus on Neumora Therapeutics, Inc. is a Moderate Buy with an average price target of $9.33, a 903.0% upside from current levels. In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

See the top stocks recommended by analysts >>

Disc Medicine (IRON)

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Disc Medicine today and set a price target of $100.00. The company’s shares closed last Monday at $69.52.

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 27.6% and a 51.4% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Amylyx Pharmaceuticals Inc. ;'>

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $100.67, which is a 45.8% upside from current levels. In a report issued on June 3, TD Cowen also initiated coverage with a Buy rating on the stock.

Read More on NMRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).